期刊
SCIENCE
卷 367, 期 6481, 页码 1001-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aba7365
关键词
-
资金
- National Institutes of Health [2R01CA120409]
- Alliance for Cancer Gene Therapy Investigator's Award
- NCI [P01 CA214278, U54 CA24711]
- NIA [U01 AG066100]
- NSF Engineering Research Center for Cell Manufacturing Technologies Seed Grant
- Abramson Cancer Center Emerging Cancer Informatics Center of Excellence Award
- Parker Institute for Cancer Immunotherapy and Tmunity Therapeutics
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase 1 clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCR alpha (TRAC) and TCR beta (TRBC), were deleted in T cells to reduce TCR mispairing and to enhance the expression of a synthetic, cancer-specific TCR transgene (NY-ESO-1). Removal of a third gene encoding programmed cell death protein 1 (PD-1; PDCD1), was performed to improve antitumor immunity. Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci. Although chromosomal translocations were detected, the frequency decreased over time. Modified T cells persisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of CRISPR gene editing for cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据